Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...

The device has evolved from one aimed at just functional MR to a broader HF therapy. EMPOWER will provide more insights.

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

This vulvar tumour case highlights the need for multidisciplinary care to manage coexisting malignancies and infections.

With healthcare rapidly evolving through digital transformation, the demand for smarter, more efficient solutions is rising, ...

While many risk factors you can’t control come into play, such as genetics and family history, there’s one you can. And ...

Medtronic's stock has been static, not delivering any gains for investors. Click here to find out why MDT stock is a Buy.